about
Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism.Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio.Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury.Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis.Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarctionVulnerable plaque versus vulnerable patient: emerging blood biomarkers for risk stratification.The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis.Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis.The CXCR4/SDF1 axis improves muscle regeneration through MMP-10 activityLack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.Effect of lutein and antioxidant supplementation on VEGF expression, MMP-2 activity, and ultrastructural alterations in apolipoprotein E-deficient mouse.Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage.proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke.Matrix metalloproteinase-10 is upregulated by thrombin in endothelial cells and increased in patients with enhanced thrombin generation.Dietary supplementation with vitamins C and E prevents downregulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro.Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stabilization.Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice.Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL.Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair.[Association of age, inflammatory markers and subclinical atherosclerosis in subjects free from cardiovascular disease].Vitamins C and e reduce retinal oxidative stress and nitric oxide metabolites and prevent ultrastructural alterations in porcine hypercholesterolemia.Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats.Expression of inducible nitric oxide synthase in smooth muscle cells from rat penile corpora cavernosa.Antioxidant effects of vitamins C and E, multivitamin-mineral complex and flavonoids in a model of retinal oxidative stress: the ApoE-deficient mouse.Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors.CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage.New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease.[Atheroma plaque stabilization: a new concept based on the dynamic biology of atherosclerosis].Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test.Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia.MMP-10 is required for efficient muscle regeneration in mouse models of injury and muscular dystrophy.The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin.C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis.Effects of cryopreservation on the immunogenicity of porcine arterial allografts in early stages of transplant vasculopathyMatrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcificationPhagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9
P50
Q28187516-28944A12-5AB8-46E3-8D05-EA4012C9575AQ34079723-F7766973-54D1-4A00-847F-3F3B5DB7D6F1Q35146507-1D57B181-9CC2-49CE-B9FA-84DA0CE9BC6AQ35146718-35008121-2C5D-4553-AD44-25C0E3EE2D66Q35559467-3F23D7A7-9DC7-4F10-A3DB-DD02451639F9Q35688512-DF7A5204-9653-4799-8C29-4EAA79B6B658Q36952402-8B371084-2478-4B98-B78D-8BEC5C1F4180Q36997866-A73000B6-B914-4A0A-8C9B-777D82B56801Q37443132-7E2E5793-F360-4BE6-9C1E-707249FBFE8BQ38895324-8CC97A14-5D1F-4A0C-B20C-39C28E932CF0Q40333177-A502C342-E16B-4087-930B-7CC48E016130Q40789168-AEB2DDC6-D0C2-4CAA-BA6C-07C1A664241BQ40812272-AB3B5C83-BAD1-4585-985C-7E3163405DAEQ42702549-C56C6693-986D-4C82-91C1-AE56D2011F7BQ42710833-C0F7254E-4D01-46B8-8BA0-0E884473751CQ43275081-6AE18B8E-D2D8-42B8-BDBE-2719FBFA636EQ44123462-C268DBB2-D1BF-414B-8FBB-52C10CF5F3C6Q44346391-251F74FD-3120-4A2D-8023-F0CF6D4AC3FFQ44671590-30215191-81C5-4ECB-BA95-E898CEE614BCQ44934450-23A79701-5399-4761-95E2-21C75BDCDB0AQ45233759-1E096543-1196-4C1D-9177-988230AB8A5BQ45857193-009B9946-010B-4751-AD79-72EAFCA6852EQ46325962-B9514A4A-0BCD-41EF-AAC5-F77DC82A18C4Q46404409-69A55448-6C7E-43C0-AAB4-3DA3E0A367F4Q46514917-8E3EF4B2-F6A7-4936-84EB-2D095E1B1BA9Q46596223-46BDFB3A-AC04-43B5-926A-628BF3517FEBQ46776385-B153D0B7-973F-4D0D-9425-C52F2D686F95Q46927729-E94FCDE6-995E-4E29-8CB9-975048DBBB26Q47165301-8A9F1F3A-A1BE-481E-8B39-698815F5BFA6Q48229194-3891FE80-E629-4E90-9BAE-642FC6CAABC9Q50551584-D89D39F9-F180-4569-B9A6-144441CAA206Q52552525-9C60FF60-F667-44E4-B25A-8BE99F660AF9Q52585182-75395307-A414-4116-8DE2-8C8B60CE9E00Q53002316-853269B7-D6E6-4D4F-9916-F0BAC5E5852FQ53086675-8F6B72C4-823A-404E-B1F3-EAB9CCBEBD38Q54589738-EF1545FE-9455-4AF3-8BBB-7128C7538E58Q54610913-EA54F623-BAEE-4B47-AB17-BC99752563F7Q57103692-0895126B-6CCA-409D-93E7-573FB11D5237Q59315333-31ED77F4-910E-4EA1-84C4-6FFD61878292Q59623212-07BDEFE5-5215-4BB5-9546-EE088A13ED92
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
José A Rodríguez
@ast
José A Rodríguez
@en
José A Rodríguez
@es
José A Rodríguez
@nl
José A Rodríguez
@sl
type
label
José A Rodríguez
@ast
José A Rodríguez
@en
José A Rodríguez
@es
José A Rodríguez
@nl
José A Rodríguez
@sl
altLabel
José A. Rodríguez García
@en
José A. Rodríguez
@en
José Antonio Rodríguez
@en
prefLabel
José A Rodríguez
@ast
José A Rodríguez
@en
José A Rodríguez
@es
José A Rodríguez
@nl
José A Rodríguez
@sl
P108
P1053
G-7324-2015
P106
P2038
Jose_Rodriguez40
P21
P31
P3829
P496
0000-0002-2094-264X